Kiromic Biopharma Inc
Change company Symbol lookup
Select an option...
KRBP Kiromic Biopharma Inc
CYPS Cyclo3pss Corp
CXW CoreCivic Inc
STM STMicroelectronics NV
NYT New York Times Co
SOS Sos Ltd
CLOV Clover Health Investments Corp
POL Polished.Com Inc
ENJYQ Legacy EJY Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Kiromic BioPharma, Inc. is an artificial intelligence (AI) driven, end-to-end allogenic cell therapy company. The Company is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.

Closing Price
Day's Change
-0.0026 (-0.98%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:
Latest Earnings Missed Consensus (Q2 ending 06/2022)Next Earnings Announcement
Announced August 12, 2022
-$0.54Q2 Consensus
of 1 analysts
-$0.38Difference from
Q3 Earnings
will announce

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.



KRBP's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.